Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201097 | 0.94 | ALDH1A1 (0.35) | ALDH1A1MAPT | |
| SCHEMBL7200114 | 0.93 | — | — | |
| SCHEMBL7199785 | 0.92 | NR3C2 (0.31) | — | |
| SCHEMBL7201776 | 0.90 | — | — | |
| SCHEMBL7205294 | 0.89 | F10 (0.31) | ALDH1A1MAPT | |
| SCHEMBL7205726 | 0.87 | MEN1 (0.30) | ALDH1A1 | |
| SCHEMBL7206508 | 0.87 | CNR1 (0.30) | — | |
| SCHEMBL7203915 | 0.86 | ADRA1D (0.33) | ALDH1A1 | |
| SCHEMBL7201125 | 0.86 | — | — | |
| SCHEMBL7201093 | 0.85 | DPP4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | claimed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | claimed |
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1234834-A1 | 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087831-A1 | 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | SERPINB1, ELANE, MMP8 | LMNA 1372/4885HCRTR1 3980/4885HCRTR2 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.